Despite a significant revenue drop, Medifast Inc (MED) surpasses guidance and focuses on innovative programs to enhance coach productivity and client engagement.

Innovent steps forward with a promising new candidate for obesity and diabetes care. IBI3032 is an orally administered ...

Discover Medifast's Q2 2025 earnings insights, highlighting a business transformation with science-backed health solutions, digital tools, and ...

Shares of Hims & Hers Health fell 13.5% in after-hours trading Monday after the telehealth company missed Wall Street’s ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Online telehealth company Hims and Hers Health missed Wall Street estimates for second-quarter revenue on Monday, as it lost subscribers for compounded versions of weight-loss drugs, sending its ...

While GLP‑1 receptor agonists may be best known for aiding weight loss and regulating digestion, gastroenterologists are also drawing attention to the therapies’ effect on the brain. Indeed, recent ...

In a small trial, people lost more weight and fat while eating a diet rich in minimally processed foods than they did eating ...

Though an estimated 17 million U.S. adolescents and young adults were eligible for GLP-1 receptor agonists for conditions like obesity and type 2 diabetes, many lacked insurance or a routine place for ...

According to expert presenters at the American Society of Preventive Cardiology’s 2025 Congress on Cardiovascular Disease Prevention, recent studies have shown significant benefit to GLP-1 inhibitors ...

Most employees said health plans should cover GLP-1 medications, with 64% saying they should and 12% saying they should not.

ABC News medical correspondent Dr. Darien Sutton talks about GLP-1 drugs and access for teens and young adults in the U.S.